Page 4 - Nasdaq Xfor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq xfor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Xfor Today - Breaking & Trending Today

X4 Pharmaceuticals (XFOR) Set to Announce Earnings on Thursday

X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) will post its quarterly earnings results before the market opens on Thursday, May 4th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.20) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link. X4 Pharmaceuticals (NASDAQ:XFOR – […] ....

Adams Mostafa , Pharmaceuticals Daily , Morgan Stanley , Jpmorgan Chase Co , Pharmaceuticals Inc , York Mellon Corp , Cantor Fitzgerald , Pharmaceuticals Trading Down , Virtu Financial , Securities Exchange Commission , Get Rating , Trading Down , Exchange Commission , Street Group , New York Mellon Corp , X4 Pharmaceuticals , Nasdaq Xfor ,

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 86.8% in April

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 3,530,000 shares, a growth of 86.8% from the March 31st total of 1,890,000 shares. Based on an average daily trading volume, of 1,340,000 shares, […] ....

Adams Mostafa , Pharmaceuticals Daily , Cantor Fitzgerald , Virtu Financial , Pharmaceuticals Trading Down , Connor Clark Lunn Investment Management Ltd , Pharmaceuticals Inc , Securities Exchange Commission , Morgan Stanley , Pharmaceuticals Company Profile , Jpmorgan Chase Co , Get Rating , Trading Down , Exchange Commission , Lunn Investment Management , Street Group , X4 Pharmaceuticals , Nasdaq Xfor ,

B. Riley Cuts X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $3.00

X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) had its price target decreased by B. Riley from $7.00 to $3.00 in a research report released on Monday morning, The Fly reports. B. Riley currently has a buy rating on the stock. A number of other equities research analysts have also recently weighed in on XFOR. HC Wainwright […] ....

Adams Mostafa , Piper Sandler , Cantor Fitzgerald , Pharmaceuticals Inc , Lexaurum Advisors , Pharmaceuticals Company Profile , Pharmaceuticals Daily , Pharmaceuticals Stock , Connor Clark Lunn Investment Management Ltd , Virtu Financial , Morgan Stanley , Get Rating , Aurum Advisors , Lunn Investment Management , Street Group , X4 Pharmaceuticals , Nasdaq Xfor , Lower Price Target , B Riley ,

Okta, Inc. (NASDAQ:OKTA) Receives Consensus Rating of "Moderate Buy" from Brokerages

X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) and Exscientia (NASDAQ:EXAI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Analyst Ratings This is a breakdown of recent ratings and […] ....

United States , United Kingdom , Renatot Skerlj , Richard Peters , Paula Ragan , Keitht Flaherty , Henria Termeer , Pharmaceuticals Daily , Pharmaceuticals Inc , Get Rating , X4 Pharmaceuticals , Nasdaq Xfor , Stock Comparison , Stock Analysis ,

FY2026 EPS Estimates for X4 Pharmaceuticals, Inc. Reduced by Analyst (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) – Equities research analysts at Oppenheimer decreased their FY2026 EPS estimates for X4 Pharmaceuticals in a research note issued on Thursday, March 23rd. Oppenheimer analyst L. Gershell now anticipates that the company will earn $0.03 per share for the year, down from their prior forecast of $0.05. Oppenheimer […] ....

Piper Sandler , Adams Mostafa , Pharmaceuticals Inc , Pharmaceuticals Stock Performance , Vanguard Group Inc , Bain Capital Life Sciences Investors , Management Company , Pharmaceuticals Daily , Lynwood Capital Management Inc , Securities Exchange Commission , Cantor Fitzgerald , Get Rating , Exchange Commission , Capital Life Sciences Investors , Lynwood Capital Management , X4 Pharmaceuticals , Nasdaq Xfor , Earnings Estimates , Oppenheimer Holdings Inc ,